NCT00944021已完成2 期
A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 69
- 主要终点
- Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).
研究概览
简要总结
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 50, 100, 150 and 200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive tuberculosis (TB). A control group will receive standard TB treatment.
详细描述
The planned sample size of 15 participants per treatment group is in keeping with other Phase II trials of this type and accounts for the possibility of up to 3 drop-outs per arm, which based on previous studies of this type conducted at these sites, represents a conservative estimate of the expected drop-out rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed Consent
- •Body weight between 40 and 90 kg, inclusive.
- •Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
- •A chest X-ray compatible with TB.
- •Sputum positive
- •Adequate volume of sputum
- •Female participants of childbearing potential negative serum pregnancy and agree to use birth control
- •Male participants must agree to use contraception throughout participation in the trial and for 12 weeks after last dose.
排除标准
- •Poor general condition
- •Rifampicin-resistant and/or Isoniazid-resistant
- •MTB Treatment received within the 3 months prior
- •Allergy to the IMP or related substances
- •Evidence of extrathoracic TB
- •A history of previous TB
- •Evidence of serious lung conditions other than TB or uncontrolled obstructive bronchial disease
- •History of lens opacity or evidence of lens opacity on slit lamp ophthalmologic examination
- •Any evidence of renal impairment
- •For males, any evidence or history of abnormality in the reproductive system
- •History and/or presence (or evidence) of neuropathy or epilepsy.
- •Clinically relevant changes in the ECG
- •A history of or current clinically relevant cardiovascular disorder
- •Concomitant use of any drug known to prolong QTc interval
- •Diabetics using insulin
- •Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).
- •Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to allergy to any TB drug, their component or to the IMP.
- •Any disease or conditions in which any of the medicinal products listed in the section pertaining to prohibited medication is used.
- •alcohol or drug abuse
- •Administration of an IMP prior to Visit 1, within 5 half-lives for that IMP if known. If the half-life of the IMP is unknown within 1 month.
- •Pregnant, breast-feeding, or planning to conceive or father a child within twelve weeks of cessation of treatment for males and within one week of cessation of treatment for females.
- •Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes
- •Any therapeutic agents known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine) within 30 days prior to dosing.
- •glucocorticoids within one year prior to dosing.
- •HIV infection with helper/inducer T lymphocyte (CD4 cell) count of less than or equal to 300x10-6/L.
- •Receiving antiretroviral therapy (ART).
研究组 & 干预措施
PA-824 50 mg/qd
Experimental
干预措施: PA-824 (Drug)
PA-824 100mg/qd
Experimental
干预措施: PA-824 (Drug)
PA-824 150mg/qd
Experimental
干预措施: PA-824 (Drug)
PA-824 200mg/qd
Experimental
干预措施: PA-824 (Drug)
Rifafour e-275mg
Active Comparator
干预措施: Rifafour e-275 mg (Drug)
结局指标
主要结局
Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).
时间窗: 14 consecutive days of treatment
次要结局
- Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14).(Days 2-14 of 14 consecutive days of treatment)
- Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14).(Fourteen consecutive days of treatment)
- Pharmacokinetics- Maximum Observed Plasma Concentration (Cmax) (Day 1).(0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment)
- Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).(Two consecutive days of treatment)
- Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2).(Two consecutive days of treatment)
- Pharmacokinetics- Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC 0 to Infinity) (Day 1).(0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment)
- Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).(Days 2-14 of 14 consecutive days of treatment)
- Pharmacokinetics-Maximum Observed Plasma Concentration (Cmax) (Day 14).(0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12,16, 24, and 30 hours post-dose on Day 14 of 14 consecutive days of treatment)
- Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 1).(0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment)
- Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 14).(0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 24 and 30 hours post-dose on Day 14 of 14 consecutive days of treatment)
研究者
相似试验
已完成
2 期
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)Pulmonary TuberculosisNCT01215110Global Alliance for TB Drug Development68
已完成
2 期
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)Pulmonary TuberculosisNCT01691534Global Alliance for TB Drug Development105
已完成
2 期
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)Pulmonary TuberculosisNCT01215851Global Alliance for TB Drug Development85
已完成
2 期
PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary TuberculosisPulmonary TuberculosisNCT00567840Global Alliance for TB Drug Development69
已完成
1 期
A Phase I Extension Trial of Repeated Infusions of ISF35Chronic Lymphocytic LeukemiaNCT00783588Memgen, LLC4